Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.
Peroxisome proliferator-activated receptors (PPARs) have been extensively studied for gene regulation in glucose and lipid metabolism. It has been recently implicated that PPARs regulate cellular proliferation and inflammatory responses; some agonists for PPARs ameliorate experimental autoimmune encephalomyelitis, a model of multiple sclerosis (MS) in humans. This article will outline current experimental evidence suggesting potential clinical benefits for patients with MS.
Department of Neurology, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku, Sapporo, 060-8638, Japan. niino@med.hokudai.ac.jp
Masaaki
M
Niino
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000737:chemistry* / Q000627:therapeutic use*; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000209:etiology; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000276:immunology / Q000502:physiology*; D000077205:Pioglitazone; D045162:Thiazolidinediones / Q000737:chemistry / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D047492:Peroxisome Proliferator-Activated Receptors; D045162:Thiazolidinediones; C039671:ciglitazone; D000077205:Pioglitazone